Canada Markets closed

Defence Therapeutics Inc. (DTC.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
5.0000-0.2000 (-3.85%)
At close: 02:16PM EST
Full screen
Previous Close5.2000
Open5.2000
Bid5.0000 x N/A
Ask5.1500 x N/A
Day's Range5.0000 - 5.2000
52 Week Range2.5600 - 8.1500
Volume3,953
Avg. Volume10,828
Market Cap179.824M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.1430
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Defence Therapeutics Achieves a Major Milestone and Begins IND-Enabling Testing of Its AccuTOX Lead Compound Against Breast Cancer

    Vancouver, British Columbia--(Newsfile Corp. - January 10, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a pre-clinical biotechnology company developing various immune-oncology products, is pleased to announce the start of its final step in GLP studies on its lead anti-cancer AccuTOXTM molecule at Eurofins Advinus Limited prior to initiate its Phase I trial in breast cancer patients. Eurofins Advinus Limited is a leading Drug Discovery ..

  • Newsfile

    Defence Therapeutics Accum(TM) Boosts by 9-Fold the Delivery Effectiveness of the CRISPR/Cas9 Protein to Target Cells

    Vancouver, British Columbia--(Newsfile Corp. - December 13, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a biotechnology company focused on the development of vaccines and therapeutics against cancer and infectious diseases, is pleased to announce that its AccumTM platform can potently enhance Cas9 delivery in target cells, which would have a significant positive impact on the CRISPR industry. The CRISPR technology offers the potential t

  • Newsfile

    Defence Therapeutics Vaccines and Program Development

    Vancouver, British Columbia--(Newsfile Corp. - November 30, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), is a publicly-traded biotechnology company working on engineering the next generation vaccines, Antibody Drug Conjugates, ADC products, and cancer therapeutics using its proprietary AccumTM platform. The core of Defence Therapeutics platform is its AccumTM technology, which enables precision delivery of proteins of pharmacological int